Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Purpose
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.
Condition
- COVID-19
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Age ≥18 years. - Informed consent for trial participation. - Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. - Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non- NAT test [list of approved tests is in the PIM] collected within the prior 14 days. - Onset of symptoms attributable to SARS-CoV2 infection occurred within 14 days before randomization. - Hospitalized for the management of COVID-19, with signs and/or symptoms suggestive of lower respiratory tract infection.
Exclusion Criteria
- The patient is expected to be discharged from the hospital within the next 24 hours. - Medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization. - Use of a strong CYP3A inducer within 14 days prior to enrollment - Moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization. - Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. - Expected inability or unwillingness to participate in study procedures. - In the opinion of the investigator, participation in a trial is not in the best interest of the patient. - Allergy to investigational agent or vehicle - Use of a concomitant medication that is contraindicated due to a drug-drug interaction with S-217622 - Moderate to severe hepatic impairment (i.e., Child-Pugh class B or C) or acute liver failure. - Known estimated glomerular filtration rate (eGRF) <30 mL/min/1.73m 2 - Continuous renal replacement therapy or chronic dialysis - Current pregnancy - Current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent. - Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent. - Men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent. - Inability to take investigational agent in tablet form by mouth.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental S-217622 (ensitrelvir) plus standard of care (SOC) |
Study investigational agent (ensitrelvir) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4. |
|
Placebo Comparator placebo plus standard of care (SOC) |
Study investigational placebo will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4. |
|
Recruiting Locations
Birmingham, Alabama 35233
Tucson, Arizona 85719
Tucson, Arizona 85723
Fresno, California 93721
Loma Linda, California 92357
VA ICC
Long Beach, California 90806
Long Beach, California 90822
Los Angeles, California 90048
Los Angeles, California 90095
Mather, California 95655
Newport Beach, California 92663
Palo Alto, California 94304
Sacramento, California 95817
Nashville ICC
San Diego, California 92161
San Francisco, California 94110
San Francisco, California 94115
San Francisco, California 94121
San Francisco, California 94143
Nashville ICC
Stanford, California 94305
Torrance, California 90502
Aurora, Colorado 80045
Aurora, Colorado 80045
Denver, Colorado 80204
New Haven, Connecticut 06510
Washington, District of Columbia 20010
Washington, District of Columbia 20422
Gainesville, Florida 32610
Miami, Florida 33125
Orlando, Florida 32827
Tampa, Florida 33606
Chicago, Illinois 60612
Urbana, Illinois 61801
Fort Wayne, Indiana 46804
Kansas City, Kansas 66160
Lexington, Kentucky 40536
Bethesda, Maryland 20892
Boston, Massachusetts 02114
Boston, Massachusetts 02215
Springfield, Massachusetts 01199
Worcester, Massachusetts 01655
Washington ICC
Ann Arbor, Michigan 48105
Detroit, Michigan 48202
Washington ICC
Detroit, Michigan 48235
Minneapolis, Minnesota 55415
Hennepin ICC
Minneapolis, Minnesota 55455
Minneapolis, Minnesota 55455
Rochester, Minnesota 55905
Jackson, Mississippi 39216
Saint Louis, Missouri 63110
Washington ICC
Omaha, Nebraska 68198
Lebanon, New Hampshire 03756
Camden, New Jersey 08103
Hackensack, New Jersey 07601
Newark, New Jersey 07103
Albuquerque, New Mexico 87106
Santa Fe, New Mexico 87505
Bronx, New York 10451
Bronx, New York 10467
Bronx, New York 10467
Bronx, New York 10468
Long Island City, New York 11102
New York ICC
New York, New York 10016
New York, New York 10029
New York, New York 10037
New York, New York 10065
Potsdam, New York 13676
Durham, North Carolina 27710
Winston-Salem, North Carolina 27157
Cincinnati, Ohio 45219
Cleveland, Ohio 44195
Columbus, Ohio 43210
Portland, Oregon 97239
Hershey, Pennsylvania 17033
Providence, Rhode Island 02903
Providence, Rhode Island 02906
Warwick, Rhode Island 02886
Charleston, South Carolina 29401
Charleston, South Carolina 29425
Rapid City, South Dakota 57701
Nashville, Tennessee 37212
Nashville ICC
Abilene, Texas 79601
Hennepin ICC
Corpus Christi, Texas 78405
Dallas, Texas 75246
Dallas, Texas 75390
Dallas, Texas 75390
Houston, Texas 77030
Houston, Texas 77030
Longview, Texas 75601
San Antonio, Texas 78229
Murray, Utah 84107
Salt Lake City, Utah 84108
Charlottesville, Virginia 22908
Salem, Virginia 24153
VA ICC
Seattle, Washington 98104
Spokane, Washington 99204
Morgantown, West Virginia 26506
Madison, Wisconsin 53705
Milwaukee, Wisconsin 53226
San Juan, Puerto Rico 00921-3201
More Details
- NCT ID
- NCT05605093
- Status
- Recruiting
- Sponsor
- University of Minnesota